DDInter119 DDInter629
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher disease, the accumulation of glucosylceramide leads to the formation of Gaucher cells that infiltrate the liver, spleen, bone marrow and other organs. This leads to complications such as anemia and thrombocytopenia.[L41404,A246384] By inhibiting glucosylceramide synthase, eliglustat reduces the accumulation of glucosylceramide. Eliglustat is mainly metabolized by CYP2D6. Patients selected for eliglustat treatment undergo an FDA-cleared genotyping test to establish if they are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs). The results of this test dictate eliglustat dosing recommendations for each type of patient. There are no dosing recommendations for CYP2D6 ultra-rapid or indeterminate metabolizers.[L41404,A7634] Eliglustat was approved by the FDA in August 2014 as an oral substrate reduction therapy for the first-line treatment of type 1 Gaucher disease.[L41404,A7634] Enzyme replacement continues to be the standard of care for the treatment of type 1 Gaucher disease ([imiglucerase], [velaglucerase alfa], [taliglucerase alfa]); however, oral substrate reduction therapies with favourable safety profiles, such as eliglustat, represent a treatment alternative.[A246389,A7634]
Eliglustat {u} may cause a minor interaction that can limit clinical effects when taken with {v} Donepezil
Eliglustat {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Eliglustat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fenfluramine
Eliglustat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naldemedine
Eliglustat {u} may lead to a major life threatening interaction when taken with {v} Bepridil
Eliglustat {u} may lead to a major life threatening interaction when taken with {v} Dacomitinib
Eliglustat may cause a minor interaction that can limit clinical effects when taken with Donepezil
Eliglustat may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine
Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Eliglustat may lead to a major life threatening interaction when taken with Bepridil
Eliglustat may lead to a major life threatening interaction when taken with Dacomitinib